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The diagnostic importance of IDH mutational status in diffuse gliomas was first formally recognized within 
the updated 4th edition of the WHO Classification of Tumours of the Central Nervous System (2016).  Its 
introduction as a diagnostic marker was based on evidence that incorporation of biomarkers into an 
integrated diagnosis provided a more reproducible and clinically meaningful classification of diffuse 
gliomas in adults [20-22]. For IDH-mutant diffuse astrocytic gliomas, the integrated diagnostic entities (and 
corresponding grades) of the 2016 WHO Classification included: Diffuse Astrocytoma, IDH-mutant (WHO 
grade II), Anaplastic Astrocytoma, IDH-mutant (WHO grade III) and  Glioblastoma, IDH-mutant (WHO 
grade IV). In contrast to IDH-mutant tumors, IDH-wildtype diffuse astrocytic gliomas are now recognized 
as distinct clinical and genetic entities that usually have much more aggressive clinical behavior, 
particularly in adults [5, 13]. While these molecular classifications represented a major step forward, 
grading schemes for the new diagnostic classes were not modified in parallel. The current grading criteria 
for diffuse astrocytic gliomas were developed prior to the understanding of molecularly distinct entities, 
yet the 2016 WHO update applies these same grading criteria for both IDH-mutant and IDH-wildtype 
gliomas [11, 14].   
 
These legacy grading systems based on morphologic features (mitotic activity, anaplastic nuclear features, 
microvascular proliferation and necrosis) are not optimal [24, 27].  In particular, multiple retrospective 
studies have concluded that histologic grading criteria may not stratify risk for patients with IDH-mutant 
astrocytomas in the WHO grade II and III categories [1, 7, 24, 27, 33]. Yet, other studies have demonstrated 
that traditional grading schemes are still capable of stratifying risk for these patients [8, 30, 32]. In an 
attempt to improve risk stratification, several studies have investigated potential morphologic, proliferative 
or molecular markers that correlate with aggressive clinical behavior and could be incorporated into a more 
clinically relevant grading scheme [1, 2, 6, 7, 26, 30-32].  
 
We evaluated the literature to determine whether there is sufficient evidence to define molecular genetic or 
other criteria that could reliably stratify risk among patients with IDH-mutant diffuse astrocytic gliomas or 
could identify those tumors that would behave most aggressively, with a clinical course corresponding to 
WHO grade IV. Among the molecular alterations considered were: CDKN2A/B homozygous deletion, 
CDK4 amplification, RB1 mutation or homozyous deletion, PIK3CA or PIK3R1 mutations, PDGFRA 
amplification, MYCN amplification, global DNA methylation levels, genomic instability and chromosome 
14 loss. We also considered whether there were thresholds of proliferative activity, based on mitotic count 
or Ki-67 indices, or other morphologic features typical of a high grade that might stratify risk better than 
current criteria. Finally, we considered potential future nosologies for IDH-mutant diffuse astrocytic 
gliomas in order to more clearly delineate these from IDH-wildtype diffuse gliomas.  To achieve these 
goals, cIMPACT-NOW assembled a group of experienced neuropathologists and clinical neuro-oncologists 
as Working Committee 1 for Round 2 discussions, which held three teleconferences in an open manner 
similar to the discussions held at WHO consensus meetings. A subsequent meeting of cIMPACT-NOW in 
Utrecht, the Netherlands in September 2019 was used to further shape the recommendations and 
justifications of Working Committee 1.  
 
Molecular Alterations Discussed for Grading of IDH-Mutant Diffuse Astrocytomas 
 
CDKN2A/B homozygous deletion 
Multiple studies have identified homozygous deletion of CDKN2A/B as a marker of poor prognosis in 
patients with IDH-mutant diffuse astrocytic gliomas [1, 2, 8, 16, 26, 30, 32, 33]. Initial observations were 
that both CDKN2A/B homozygous deletions and CDK4 amplification were enriched among IDH-mutant 
astrocytomas that were associated with poor prognosis, and that this subset also showed lower levels of 
global DNA methylation (G-CIMP-low) [6]. Subsequent investigations of CDKN2A/B homozygous 
deletion as an independent marker in WHO grade II and III IDH-mutant astrocytic gliomas confirmed a 
strong association with shorter survival [7, 8, 26, 33]. A more recent study demonstrated that CDKN2A/B 
homozygous deletion was strongly associated with a poor prognosis in a cohort that included all grades of 
IDH-mutant astrocytomas (WHO grades II-IV) on univariable analysis [30]. In particular, CDKN2A/B 
homozygous deletions in histologic grade III IDH-mutant astrocytomas were associated with shorter patient 
survival, similar to WHO grade IV tumors [30]. Other investigations have corroborated these findings [2, 
16, 30]. The frequencies of CDKN2A/B homozygous deletions reported in IDH-mutant astrocytic gliomas 
range from 0-12% in WHO grade II, 6-20% in WHO grade III and 16-34% in WHO grade IV tumors [2, 
30, 32]. It should be noted that the prognostic associations reported for CNKN2A/B homozygous deletion 
have been based on retrospective cohorts with potentially confounding prognostic parameters, notably age 
and divergent patterns of care. Moreover, homozygous deletion at 9p21 not only targets the CDKN2A/B 
locus, but also other neighboring genes that have known or suspected tumor suppressive functions [3, 15, 
29]. 
 
Alteration of other RB pathway genes 
CDK4 amplification in IDH-mutant astrocytomas was associated with poor prognosis and its combination 
with chromosome 14 loss predicted an even shorter overall survival [7, 8]. Other studies have concluded 
that CDK4 amplification was not associated with poor prognosis [2, 30].  Homozygous deletion of RB1 was 
strongly associated with inferior overall survival among IDH-mutant astrocytomas on univariate analysis, 
but this finding was not corroborated in other investigations [2, 30]. In a multivariate analysis of two sizable 
patient cohorts, Aoki et al. demonstrated that altered RB pathway genes (CDKN2A/B homozygous deletion, 
CDK4 amplification or RB1 mutation), when considered together, were a strong and statistically significant 
predictor of poor prognosis in IDH-mutant astrocytoma patients [1]. When considered by themselves in this 
study, each of these markers was associated with a less favorable prognosis, although not significantly on 
univariate analysis. The prognostic role of less common RB pathway gene alterations, such as CDKN2A/B 
point mutation, CDKN2A/B promoter methylation or CDK6 amplification remains unclear and deserves 
further study.  
PIK3R1 and PIK3CA mutations 
On multivariate analysis, PIK3R1 mutations were an independent marker of poor prognosis in IDH-mutant 
astrocytomas of WHO grade II or III. PIK3CA mutations showed a strong trend towards shorter overall 
survival but were not an independent marker on multivariable analysis [1].  
 
PDGFRA amplification 
Multiple studies have demonstrated that PDGFRA amplification is associated with shorter survival among 
patients with IDH-mutant astrocytic gliomas, including a recent investigation showing its prognostic 
significance specifically in histologic grade II and III tumors on multivariable analysis [25, 30, 32]. Another 
study did not uncover this association [1].  
 
MYCN amplification 
MYCN amplification was associated with shorter overall survival in patients with IDH-mutant astrocytomas 
(WHO grades II-IV) on univariable analysis [30]. 
 
Genomic instability 
Both high levels of copy number variations (CNV) and somatic mutations have been associated with higher 
histologic grade among IDH-mutant astrocytomas and with shorter overall survival in patients with WHO 
grade II or III IDH-mutant astrocytomas [1, 9, 28]. In a separate investigation, patients with IDH-mutant 
astrocytomas that displayed a high CNV level had shorter overall survival than those with low CNV level 
[30]. There are challenges in the comparison and interpretation of these investigations, since the thresholds 
for high CNV and somatic mutation varied [23]. 
 
Reduced global DNA methylation 
In a study of 1,122 diffuse gliomas, a small subset of IDH-mutant diffuse astrocytic gliomas (WHO grades 
II-IV) were found to have globally reduced levels of DNA methylation (G-CIMP-low) relative to the 
majority of IDH-mutant astrocytomas, as well as a distinctive gene expression profile [6]. Half of these G-
CIMP-low gliomas corresponded to WHO grade IV and the other half were histologically WHO grade II 
or III. Patients with G-CIMP-low IDH-mutant astrocytomas had shorter overall survival than patients in 
the G-CIMP-high group. More than 75% of the G-CIMP-low tumors had alterations in RB pathway genes 
(CDKN2A/B homozygous deletion and CDK4 amplification). Another study, focused exclusively on IDH-
mutant glioblastoma, WHO grade IV, confirmed both the short survival of patients with G-CIMP-low 
tumors and the association with CDKN2A/B homozygous deletion [17]. 
 
Other genetic markers 
Other genetic markers of interest did not show strong evidence for the ability to stratify risk among patients 
with IDH-mutant astrocytomas or predict WHO grade IV behavior.  Larger or additional studies may 
provide stronger evidence in the future [6, 8, 12, 24, 30].  
 
Mitotic activity and proliferation indices 
The traditional method for stratifying risk among histologic grade II or III diffuse astrocytic gliomas has 
relied heavily on the identification of mitotic activity. The WHO 2016 indicates that “significant 
proliferative activity” distinguishes anaplastic astrocytoma, IDH-mutant, WHO grade III from diffuse 
astrocytoma, IDH mutant, WHO grade II [20]. Based on studies in the pre-WHO 2016 era, astrocytomas 
with ≥ 2 mitoses in the entire specimen have been shown to be associated with shorter survival than those 
with 0 or 1 mitoses and this threshold has therefore been used by practicing neuropathologists for the 
designation of WHO grade III [10, 11, 14]. Specimen size must also be considered. In a very small biopsy, 
one mitosis may be sufficient, whereas in very large specimens, greater mitotic activity may be necessary 
[20]. These thresholds for mitotic activity have not been corroborated by several studies of IDH-mutant 
cohorts [12, 24, 33]. However, others have demonstrated that traditional grading schemes can stratify risk 
among patients with grade II and III IDH-mutant astrocytomas, but with ample opportunity for 
improvement [8, 30, 32]. To date, there have been no studies that establish an alternative mitotic count that 
more reliably stratifies risk among histologic grade II and III IDH-mutant astrocytomas. Similarly, studies 
of proliferative index (e.g. based on Ki-67) have not identified criteria that unequivocally stratify risk 
among patients with IDH-mutant astrocytomas [12]. 
 
Summary of findings 
The currently available evidence from multiple retrospective studies suggests that homozygous deletion of 
CDKN2A/B is associated with shorter survival in patients with IDH-mutant astrocytomas and that its 
presence corresponds to WHO grade IV clinical behavior. Alterations in other genes encoding members of 
the RB pathway, including CDK4 amplification or RB1 mutation/homozygous deletion, may also be 
markers of aggressive clinical behavior but the evidence is not as firmly established (e.g., fewer cases or 
fewer published studies). Several studies have demonstrated PDGFRA amplification as a marker of poor 
prognosis with potential for inclusion as a grading criterion with additional corroborating evidence. While 
mutations in PIK3R1 and PIK3CA, as well as amplifications in MYCN, have been associated with shorter 
survival, additional cohorts are needed for validation. Genomic instability is a feature corresponding to poor 
prognosis in patients with IDH-mutant astrocytomas. However, the analyses and thresholds for clinical 
validation of genomic instability have not been firmly established for application to clinical practice. 
Similarly, G-CIMP-low DNA methylation pattern has been associated with shorter survival in IDH-mutant 
astrocytoma, but additional cohorts are needed for validation to more precisely define the G-CIMP-low 
methylation diagnostic profile as well as to assess the practicality of testing modalities. There is currently 
insufficient evidence to establish a new threshold of mitotic activity to discriminate histologic grade II and 
III IDH-mutant astrocytomas. Overall, with regard to clinical outcomes and grading criteria, we have been 
cautious in our interpretation of the literature, since most large studies on the relationship between genetic 
alterations and clinical outcomes have relied on retrospective cohorts in which patients had been treated 
differently depending on institution, era and histologic classification. Moreover, clinical follow-up times 
are limited in most studies, which is a particular weakness when assessing prognostic markers in patients 
whose median overall survival is beyond 10 years. 
Proposed Terminology for next WHO classification 
The terms used to classify the diffusely infiltrative gliomas are deeply rooted in history and based on 
presumed tumor cell lineage and levels of differentiation. For the diffuse astrocytic gliomas, we now 
understand that IDH-wildtype and IDH-mutant tumors represent distinct clinical and genetic entities, 
despite the similar terms used for their classification by the WHO (diffuse astrocytoma, anaplastic 
astrocytoma and glioblastoma). Terminologies that more clearly distinguish IDH-mutant and IDH-wildtype 
diffuse astrocytic gliomas are desirable. One suggestion was to reserve the term “glioblastoma” for those 
diffuse astrocytic gliomas that are IDH-wildtype and have histologic or genetic features predictive of a 
highly aggressive clinical behavior corresponding to WHO grade IV [4]. Diffuse astrocytic gliomas that 
are IDH-mutant would be graded based upon morphologic and genetic features that corresponded to WHO 
grade II, III or IV clinical behavior. The suggested terminologies, class definitions, and grading criteria for 
IDH-mutant astrocytomas are summarized in Table 1. We recognize that changes of this type may be 
viewed as controversial and will require further discussion in context of the next WHO classification, which 
is scheduled for later 2020 (see Supplemental Text for critiques and responses). Note the use of the Arabic 
numerals 2, 3 and 4, rather than the Roman numerals II, III and IV, that had traditionally been used for 
WHO CNS tumor grades; Arabic numerals are suggested in order to harmonize with WHO grading schemes 
of other tumor types and to reduce the possibility of introducing typographical and interpretive errors (i.e., 









Table 1.  IDH-mutant Astrocytomas 
Astrocytoma, IDH-mutant, WHO grade 2 
A diffusely infiltrative astrocytic glioma with an IDH1 or IDH2 mutation that is well differentiated and 
lacks histologic features of anaplasia. Mitotic activity is not detected or low*.  Microvascular proliferation, 
necrosis and CDKN2A/B homozygous deletions are absent. 
 
Astrocytoma, IDH-mutant, WHO grade 3 
A diffusely infiltrative astrocytic glioma with an IDH1 or IDH2 mutation that exhibits focal or dispersed 
anaplasia and displays significant mitotic activity*. Microvascular proliferation, necrosis and CDKN2A/B 
homozygous deletions are absent. 
 
Astrocytoma, IDH-mutant, WHO grade 4 
A diffusely infiltrative astrocytic glioma with an IDH1 or IDH2 mutation that exhibits microvascular 
proliferation or necrosis or CDKN2A/B homozygous deletion or any combination of these features.  
*= see text regarding mitotic count cut-off values 
 
Grading considerations for IDH-mutant astrocytomas.  
IDH-mutant astrocytomas that lack significant mitotic activity, histologic anaplasia, microvascular 
proliferation, necrosis and CDKN2A/B homozygous deletion are referred to as Astrocytoma, IDH-mutant, 
WHO grade 2. Patients with these tumors have a median overall survival greater than 10 years [2, 30].  An 
IDH-mutant astrocytoma that contains elevated mitotic activity and histologic anaplasia, yet lacks 
microvascular proliferation, necrosis and CDKN2A/B homozygous deletion, currently fits into the 
designation of Astrocytoma, IDH-mutant, WHO grade 3. Recognizing that no validated published criteria 
exist for mitotic count cut-off values for grading IDH-mutant astrocytomas, “significant” mitotic activity 
remains the criterion to distinguish WHO grade 3 from grade 2 tumors. Most neuropathologists use a 
threshold of ≥ 2 mitoses within the entire specimen, or 1 mitosis in very small biopsies, while large 
specimen may require more [10, 14, 20].  The extent to which Astrocytoma, IDH-mutant, WHO grade 3 
exhibits clinically more aggressive behavior relative to its WHO grade 2 counterpart remains to be 
determined. It should be noted that future studies may refine mitotic thresholds for grading and may identify 
additional genetic alterations associated with more aggressive clinical behavior among WHO grade 2 and 
3 IDH-mutant astrocytomas.  
 
IDH-mutant astrocytomas with microvascular proliferation or necrosis or CDKN2A/B homozygous 
deletion, or any combination of these features, correspond to WHO grade 4. These tumors have been 
formerly considered as "Glioblastoma, IDH-mutant, WHO grade IV". However, they are clinically and 
genetically distinct from glioblastoma, IDH-wildtype, and closely related to WHO grade 2 or 3 IDH-mutant 
astrocytomas. Thus, cIMPACT-NOW recommends that the WHO strongly consider discontinuing the term 
"Glioblastoma, IDH-mutant, WHO grade IV" and instead recommends referring to these tumors as 
“Astrocytoma, IDH-mutant, WHO grade 4”. Based on the strength of evidence, cIMPACT-NOW also 
recommends that CDKN2A/B homozygous deletion should be a WHO grade 4 criterion for IDH-mutant 
astrocytomas. Some studies have concluded that homozygous deletion of CDKN2A/B is associated with 
worse outcome even among patients with histologically defined WHO grade 4 IDH-mutant astrocytomas 
[16, 30]. Homozygous deletion can be determined by FISH, quantitative PCR, MLPA, microarray- or NGS-
based methods. However, immunohistochemistry for p16 does not correlate well with deletion [26]. 
 
These recommendations represent the initial steps toward advancing our ability to distinguish clinically 
relevant subgroups of IDH-mutant astrocytomas at a diagnostic level, and in turn guide patient care and 
inclusion into clinical trials. In combination with the other cIMPACT-NOW updates, it is further anticipated 
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Supplemental Text 
Reviewers’ Primary Critiques and Authors’ Responses to Proposed Grading and Terminologies 
in cIMPACT-NOW Update 5 
Critique:  The WHO 2016 Update of the 4th Edition introduced IDH-wildtype and IDH-mutant astrocytic 
gliomas as distinct entities, which is sufficient for diagnostic and treatment purposes. There is no need 
to eliminate the term glioblastoma for IDH-mutant astrocytic gliomas, since this will result in confusion.   
Response:  In 2016, the Updated 4th Edition of the WHO introduced IDH-mutant and IDH-wildtype forms 
of diffuse astrocytoma, anaplastic astrocytoma and glioblastoma, which was a justified and necessary 
first step in delineating these diseases. However, cIMPACT-NOW Working Committee 1 was concerned 
that the exact same names were applied to diseases that were distinct. We concluded that referring to 
IDH-mutant and IDH-wildtype forms of these diseases by using the same terms (e.g. glioblastoma) 
perpetuates the misconception of these tumors as variants of the same disease process (i.e. “the good 
prognosis form of GBM” or “GBM with a prognostically favorable mutation”). Rather, IDH-mutant and 
IDH-wildtype forms of astrocytic gliomas differ based on their clinical demographics and presentation, 
genetics, epigenetics and behavior, and will require separate treatments and clinical trials based on their 
diagnosis. Given that IDH-mutant and IDH-wildtype astrocytic gliomas are separate and specific diseases, 
our Committee concluded that they should have separate and specific terminologies. We proposed to 
reserve the term Glioblastoma for IDH-wildtype astrocytic gliomas of grade IV. With regard to clinical 
care and enrollment on clinical trials, the Committee concluded that there would be less confusion by 
eliminating the use of similar terms for different diseases. 
 
Critique:  The rationale for using Arabic numerals instead of Roman numerals is not strong. This change 
will result in confusion, since pathologists and clinicians are familiar with Roman numerals for grading.  
Response: The WHO has strongly signaled that standardization of terminologies and style will be 
expected across all tumor types going forward in the upcoming 5th Edition. The vast majority of WHO 
tumor classifications have used Arabic for grading purposes and this will almost certainly be the 
standardized practice moving forward.  For example, the first two publications of the 5th Edition WHO 
Classification—Breast Tumours and Tumours of the Digestive System--have both used Arabic numerals 
for those tumors that require numerical grading. In addition, there is a practical point in using Arabic 
numerals in that typographical and interpretive errors are much less likely with the use of Arabic 
numerals (grades 2 vs 3) than with Roman numerals (grades II vs III).  
 
Critique:   cIMPACT-NOW should have been bolder and more ambitious in their recommendations for 
molecular grading criteria, since it is well known that morphologic grading criteria are not optimal for 
stratifying risk. Wouldn't it be easier to classify and grade these tumors on the basis of the molecular 
profiling only? 
 
Response: cIMPACT-NOW Working Committee 1 evaluated the literature to determine if there were 
morphologic or genetic markers that could more optimally stratify risk among IDH-mutant astrocytomas 
and be utilized to improve grading criteria. We concluded that the evidence was strong for CDKN2A/B 
homozygous deletion as a marker of grade 4 behavior and have included it in the proposal for a revised 
grading scheme. We did not identify other morphologic, proliferative or genetic markers that have been 
reproducibly demonstrated to improve risk stratification in IDH-mutant astrocytomas and could be used 
clinically. Morphologic markers still play a large role in grading IDH-mutant astrocytomas.  Microvascular 
proliferation and necrosis are associated with grade 4 behavior and have excellent reproducibility and 
predictive value. We agree that additional studies will be necessary to improve prognostication, risk 
stratification and grading schemes for grade 2 and grade 3 IDH-mutant astrocytomas. 
 
Critique: The morphologic criteria for distinguishing grade 2 from grade 3 have not changed from the 
WHO 2016 4th Edition Update. Why doesn’t cIMPACT provide new criteria based on mitoses per high 
power field (HPF) or mitoses per mm2? 
Response:  A major conclusion from our cIMPACT-NOW discussions was that there was no solid 
evidence in the literature for improved grading criteria to distinguish grade 2 and grade 3 IDH-mutant 
astrocytomas. Therefore, the morphologic criteria for distinguishing grade 2 from grade 3 in cIMPACT-
NOW Update 5 are the same as those in the 2016 WHO classification. With regard to providing a 
“mitotic count/HPF” or “mitotic count/mm2”, we are not aware of studies that have shown such 
thresholds for discriminating grade 2 from grade 3 IDH-mutant astrocytomas. Lacking evidence for 
change, we opted to continue with WHO 2016 criteria, with the exception of including CDKN2A/B 
homozygous deletion as a grade 4 criterion. 
 
Critique: The criterion of  “≥2 mitoses" for distinguishing grade 2 from grade 3 IDH-mutant astrocytomas 
is confusing. Is this ≥2 mitoses per field, per 10 high-power fields, or per entire specimen? Who 
established these criteria? This is not common practice. The references cited for these criteria are old 
and questionable.  
Response:  The criteria used for grading diffuse astrocytic neoplasms has evolved over time. The WHO 
1st edition (1979) used “areas of anaplasia” as the criterion for establishing a diagnosis of anaplastic 
astrocytoma, grade 3. Mitotic activity was not a criterion in the 1st edition. In a study of morphologic 
features of astrocytic neoplasms and their associations with clinical outcomes, Daumas-Duport et al 
concluded that nuclear atypia and any mitotic activity (these were 2 of the four features included in the 
study, along with microvascular hyperplasia and necrosis) could be used to stratify grade 3 from grade 2 
and led to the Mayo-St. Anne criteria (1988)[5].  Importantly, this study concluded that the presence of 
any mitoses identified within the entire specimen (≥ 1) was associated with a shorter survival and 
distinguished grade 3 from grade 2 clinical behavior among astrocytomas. Based on these findings, the 
WHO 2nd edition (1993) used “mitotic activity” (any in the specimen) to distinguish anaplastic 
astrocytoma, grade 3 from astrocytoma, grade 2. The findings of the Mayo-St. Anne criteria were 
confirmed in an independent cohort in 1998 by Coons and Pearl, who demonstrated that the presence 
of 1 mitosis in the entire specimen stratified patients with long survival (grade 2) from those with 
intermediate survival (grade 3)[4].  In 1998, Giannini et al investigated whether other levels of mitotic 
activity might stratify risk better than any (≥ 1) mitoses per specimen [6]. They found that astrocytomas 
with ≤ 1 (either 0 or 1) mitoses in the entire specimen were associated with survivals similar to grade 2 
astrocytomas and longer than anaplastic astrocytoma, grade 3. These results indicated that the finding 
of 1 mitotic figure was not sufficient to predict grade 3 behavior in astrocytomas. This led the WHO 3rd 
edition (2000) to add “a single mitosis does not yet allow the diagnosis of anaplastic astrocytoma” (i.e. 
grade 3) and also stated that a grade 2 designation was appropriate if mitoses are “very rare or absent”. 
In this same edition, anaplastic astrocytoma, grade 3, was defined as having “marked mitotic activity”, 
with no precise values provided.  In the WHO 4th edition (2007), the criteria for diffuse astrocytoma, 
WHO grade 2 indicated that “a single mitosis does not allow the diagnosis of anaplastic astrocytoma”, 
without an area provided and therefore continued the practice of using ≥ 2 mitoses in the entire 
specimen as the threshold. In the updated 4th edition of the WHO (2016), Diffuse astrocytoma, IDH 
mutant, WHO grade 2 and Anaplastic astrocytoma, IDH mutant, WHO grade 3 were introduced. Since 
there were no definitive studies of morphologic features (i.e. mitoses, etc) and clinical outcomes on IDH-
mutant astrocytomas, the criteria for distinguishing grade 3 from grade 2 remained largely the same. For 
grade 2:  “Mitotic activity is generally absent but a single mitosis does not justify the diagnosis of 
anaplastic astrocytoma unless observed in a small biopsy or in the setting of obvious nuclear anaplasia”. 
In the description of anaplastic astrocytoma, IDH mutant, WHO grade 3, it is stated “The principal 
histopathological features are those of a diffusely infiltrating astrocytoma with increased mitotic activity 
compared with the WHO II equivalent, usually accompanied by distinct nuclear atypia and high 
cellularity. Mitotic activity should be evaluated in the context of sample size”.  It was here that the idea 
that sampling size should be taken into consideration for establishing a grade 2 or grade 3 using mitotic 
activity.  These statements were justified based on the findings of Coons and Pearl (1998) that the 
identification of mitoses depended upon the number of fields viewed[4]. 
Thus, the mitotic threshold for distinguishing grade 2 and 3 astrocytomas is ≥ 2 mitoses in the entire 
specimen, with appropriate consideration to the size of specimen. We have not deviated from the WHO 
2016 nor from the tradition that it has continued. There are a few studies that have shown that the 
WHO criteria can be used to stratify risk among patients with grade 2 versus 3 IDH-mutant astrocytomas 
[3, 9, 10]. In contrast, other studies have not been able to demonstrate a significant prognostic role of 
WHO grading and/or mitotic count in IDH-mutant astrocytoma patients [1, 2, 7, 8, 11]. Because there is 
not sufficient evidence to introduce a change in grading criteria for grade 2 and grade 3 IDH-mutant 
astrocytomas, we have adhered to the WHO 2016 criteria and acknowledge the need for additional 
studies. We agree that several of the references cited are old and may be questionable in the current 
molecular era. There are simply no better data currently available.  
 
Critique:  When proposing a change in grading, which is intended to correspond to clinical behavior (in 
this case grades 2, 3, and 4), a comparative survival analysis should be performed with other tumors to 
ensure consistency of outcomes with respect to grade. The current grading proposal (2, 3, 4) is not 
normalized to clinical outcome with other entities.  
Response: Grading of neoplasms based upon WHO guidelines and criteria is not precisely uniform or 
normalized with regard to clinical outcomes across CNS (or non-CNS) tumors. Grading is intended to 
reflect the natural history of untreated neoplasms. We do not currently have good evidence on the 
natural history of IDH-mutant astrocytomas. We rely heavily on the clinical outcomes from retrospective 
studies of treated patient cohorts to provide correlations of clinical outcomes with specific grading 
criteria. Grading criteria will be improved with the availability of solid evidence published and validated 
in the literature.  There are many examples of tumors with similar grades that have differing clinical 
outcomes.  For example, the genetic and morphologic subtypes of medulloblastoma are all considered 
grade 4 based on their natural histories, yet are associated with substantially different clinical outcomes 
when patients are being treated according to current standard of care. Even with the best data 
available, it would not be expected that a cohort of patients with IDH-mutant astrocytoma, WHO grade 
4 would have clinical outcomes similar or identical to a cohort of patients with glioblastoma, IDH-
wildtype, WHO grade 4. However, both cohorts have diseases that are associated with aggressive clinical 
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